A prospective multicenter trial by Hofman et al. demonstrated that PSMA PET-CT significantly outperforms conventional imaging for both sensitivity (92% vs. 65%) and specificity (95% vs. 74%) in the initial staging of high-risk PCa, influencing treatment intent in 28% of patients [3]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.